 - Patients must have measurable disease by RECIST criteria for the Phase II portion. Disease in previously irradiated sites is considered measurable if there is clear disease progression following radiation therapy. Patients with evaluable disease bone metastases, pleural fluid, ascites, etc. may be included in the phase I portion of the trial completed 100808. 